Cardiac Drug Development Guide:
The revolution in molecular medicine makes it imperative to integrate the classical and molecular approaches to drug development for the treatment of heart disease, the number one killer in North America and Europe. In the Cardiac Drug Development Guide, basic medical researchers, clinicians, and ph...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Totowa, NJ
Humana Press
2003
|
| Schriftenreihe: | Methods in Pharmacology and Toxicology
|
| Schlagworte: | |
| Online-Zugang: | UBR01 TUM01 Volltext |
| Zusammenfassung: | The revolution in molecular medicine makes it imperative to integrate the classical and molecular approaches to drug development for the treatment of heart disease, the number one killer in North America and Europe. In the Cardiac Drug Development Guide, basic medical researchers, clinicians, and pharmacologists join forces to comprehensively survey the most recent breakthroughs in molecular cardiology and review the latest drug discoveries in cardiac and cardiovascular medicine. Topics range from novel molecular targets for cardiac drug development, to functional endpoints for evaluating cardiac drug activity, to clinical aspects of cardiovascular therapeutics. The authors describe the most advanced procedures in cardiovascular pharmacology, including in vivo and in vitro whole animal studies, the electrophysiological methods used to study pacemaker cells, and the application of biochemical principles and technologies to novel therapeutic agents. Also discussed are the methods used to express the ion channels involved in cardiovascular pharmacology, adenoviral vector delivery for cardiovascular gene therapy, pharmacometrics in cardiovascular drug development, gender differences in heart failure, and angiogenesis therapies for coronary heart disease. Each chapter concisely illustrates the concepts described and includes comprehensive background information, detailed figures and tables, and an up-to-date list of the most important references. Comprehensive and easy-to-understand, the Cardiac Drug Development Guide offers pharmacologists, cardiologists, and physiologists not only a gold-standard survey of the many different methods being used to develop new heart drugs, but also details powerful new ways in which cardiovascular disease is targeted, from the whole organ to the genetic level |
| Beschreibung: | 1 Online-Ressource (X, 431 p) |
| ISBN: | 9781592594047 |
| DOI: | 10.1385/1592594042 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV044951608 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 180517s2003 |||| o||u| ||||||eng d | ||
| 020 | |a 9781592594047 |9 978-1-59259-404-7 | ||
| 024 | 7 | |a 10.1385/1592594042 |2 doi | |
| 035 | |a (ZDB-2-PRO)978-1-59259-404-7 | ||
| 035 | |a (OCoLC)1036332745 | ||
| 035 | |a (DE-599)BVBBV044951608 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 |a DE-91 | ||
| 082 | 0 | |a 615.1 |2 23 | |
| 245 | 1 | 0 | |a Cardiac Drug Development Guide |c edited by Michael K. Pugsley |
| 264 | 1 | |a Totowa, NJ |b Humana Press |c 2003 | |
| 300 | |a 1 Online-Ressource (X, 431 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Methods in Pharmacology and Toxicology | |
| 520 | |a The revolution in molecular medicine makes it imperative to integrate the classical and molecular approaches to drug development for the treatment of heart disease, the number one killer in North America and Europe. In the Cardiac Drug Development Guide, basic medical researchers, clinicians, and pharmacologists join forces to comprehensively survey the most recent breakthroughs in molecular cardiology and review the latest drug discoveries in cardiac and cardiovascular medicine. Topics range from novel molecular targets for cardiac drug development, to functional endpoints for evaluating cardiac drug activity, to clinical aspects of cardiovascular therapeutics. The authors describe the most advanced procedures in cardiovascular pharmacology, including in vivo and in vitro whole animal studies, the electrophysiological methods used to study pacemaker cells, and the application of biochemical principles and technologies to novel therapeutic agents. Also discussed are the methods used to express the ion channels involved in cardiovascular pharmacology, adenoviral vector delivery for cardiovascular gene therapy, pharmacometrics in cardiovascular drug development, gender differences in heart failure, and angiogenesis therapies for coronary heart disease. Each chapter concisely illustrates the concepts described and includes comprehensive background information, detailed figures and tables, and an up-to-date list of the most important references. Comprehensive and easy-to-understand, the Cardiac Drug Development Guide offers pharmacologists, cardiologists, and physiologists not only a gold-standard survey of the many different methods being used to develop new heart drugs, but also details powerful new ways in which cardiovascular disease is targeted, from the whole organ to the genetic level | ||
| 650 | 4 | |a Pharmacy | |
| 650 | 4 | |a Pharmacy | |
| 650 | 4 | |a Pharmacy | |
| 700 | 1 | |a Pugsley, Michael K. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781588290977 |
| 856 | 4 | 0 | |u https://doi.org/10.1385/1592594042 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-PRO | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-030344365 | ||
| 966 | e | |u https://doi.org/10.1385/1592594042 |l UBR01 |p ZDB-2-PRO |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1385/1592594042 |l TUM01 |p ZDB-2-PRO |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804178540446351360 |
|---|---|
| any_adam_object | |
| author2 | Pugsley, Michael K. |
| author2_role | edt |
| author2_variant | m k p mk mkp |
| author_facet | Pugsley, Michael K. |
| building | Verbundindex |
| bvnumber | BV044951608 |
| collection | ZDB-2-PRO |
| ctrlnum | (ZDB-2-PRO)978-1-59259-404-7 (OCoLC)1036332745 (DE-599)BVBBV044951608 |
| dewey-full | 615.1 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.1 |
| dewey-search | 615.1 |
| dewey-sort | 3615.1 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1385/1592594042 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03179nmm a2200409zc 4500</leader><controlfield tag="001">BV044951608</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">180517s2003 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781592594047</subfield><subfield code="9">978-1-59259-404-7</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1385/1592594042</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-PRO)978-1-59259-404-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1036332745</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044951608</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-91</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.1</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cardiac Drug Development Guide</subfield><subfield code="c">edited by Michael K. Pugsley</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Totowa, NJ</subfield><subfield code="b">Humana Press</subfield><subfield code="c">2003</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (X, 431 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Methods in Pharmacology and Toxicology</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The revolution in molecular medicine makes it imperative to integrate the classical and molecular approaches to drug development for the treatment of heart disease, the number one killer in North America and Europe. In the Cardiac Drug Development Guide, basic medical researchers, clinicians, and pharmacologists join forces to comprehensively survey the most recent breakthroughs in molecular cardiology and review the latest drug discoveries in cardiac and cardiovascular medicine. Topics range from novel molecular targets for cardiac drug development, to functional endpoints for evaluating cardiac drug activity, to clinical aspects of cardiovascular therapeutics. The authors describe the most advanced procedures in cardiovascular pharmacology, including in vivo and in vitro whole animal studies, the electrophysiological methods used to study pacemaker cells, and the application of biochemical principles and technologies to novel therapeutic agents. Also discussed are the methods used to express the ion channels involved in cardiovascular pharmacology, adenoviral vector delivery for cardiovascular gene therapy, pharmacometrics in cardiovascular drug development, gender differences in heart failure, and angiogenesis therapies for coronary heart disease. Each chapter concisely illustrates the concepts described and includes comprehensive background information, detailed figures and tables, and an up-to-date list of the most important references. Comprehensive and easy-to-understand, the Cardiac Drug Development Guide offers pharmacologists, cardiologists, and physiologists not only a gold-standard survey of the many different methods being used to develop new heart drugs, but also details powerful new ways in which cardiovascular disease is targeted, from the whole organ to the genetic level</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacy</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pugsley, Michael K.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781588290977</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1385/1592594042</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-PRO</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030344365</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1385/1592594042</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-PRO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1385/1592594042</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-2-PRO</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV044951608 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:05:36Z |
| institution | BVB |
| isbn | 9781592594047 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-030344365 |
| oclc_num | 1036332745 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR DE-91 DE-BY-TUM |
| owner_facet | DE-355 DE-BY-UBR DE-91 DE-BY-TUM |
| physical | 1 Online-Ressource (X, 431 p) |
| psigel | ZDB-2-PRO |
| publishDate | 2003 |
| publishDateSearch | 2003 |
| publishDateSort | 2003 |
| publisher | Humana Press |
| record_format | marc |
| series2 | Methods in Pharmacology and Toxicology |
| spelling | Cardiac Drug Development Guide edited by Michael K. Pugsley Totowa, NJ Humana Press 2003 1 Online-Ressource (X, 431 p) txt rdacontent c rdamedia cr rdacarrier Methods in Pharmacology and Toxicology The revolution in molecular medicine makes it imperative to integrate the classical and molecular approaches to drug development for the treatment of heart disease, the number one killer in North America and Europe. In the Cardiac Drug Development Guide, basic medical researchers, clinicians, and pharmacologists join forces to comprehensively survey the most recent breakthroughs in molecular cardiology and review the latest drug discoveries in cardiac and cardiovascular medicine. Topics range from novel molecular targets for cardiac drug development, to functional endpoints for evaluating cardiac drug activity, to clinical aspects of cardiovascular therapeutics. The authors describe the most advanced procedures in cardiovascular pharmacology, including in vivo and in vitro whole animal studies, the electrophysiological methods used to study pacemaker cells, and the application of biochemical principles and technologies to novel therapeutic agents. Also discussed are the methods used to express the ion channels involved in cardiovascular pharmacology, adenoviral vector delivery for cardiovascular gene therapy, pharmacometrics in cardiovascular drug development, gender differences in heart failure, and angiogenesis therapies for coronary heart disease. Each chapter concisely illustrates the concepts described and includes comprehensive background information, detailed figures and tables, and an up-to-date list of the most important references. Comprehensive and easy-to-understand, the Cardiac Drug Development Guide offers pharmacologists, cardiologists, and physiologists not only a gold-standard survey of the many different methods being used to develop new heart drugs, but also details powerful new ways in which cardiovascular disease is targeted, from the whole organ to the genetic level Pharmacy Pugsley, Michael K. edt Erscheint auch als Druck-Ausgabe 9781588290977 https://doi.org/10.1385/1592594042 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Cardiac Drug Development Guide Pharmacy |
| title | Cardiac Drug Development Guide |
| title_auth | Cardiac Drug Development Guide |
| title_exact_search | Cardiac Drug Development Guide |
| title_full | Cardiac Drug Development Guide edited by Michael K. Pugsley |
| title_fullStr | Cardiac Drug Development Guide edited by Michael K. Pugsley |
| title_full_unstemmed | Cardiac Drug Development Guide edited by Michael K. Pugsley |
| title_short | Cardiac Drug Development Guide |
| title_sort | cardiac drug development guide |
| topic | Pharmacy |
| topic_facet | Pharmacy |
| url | https://doi.org/10.1385/1592594042 |
| work_keys_str_mv | AT pugsleymichaelk cardiacdrugdevelopmentguide |